Kalbe Farma stock falls 14.56 percent to IDR 675.00

Published on 10/16/2026 at 16:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Morgan Stanley retained an IDR 880.00 target on September 16, 2026. Kalbe Farma stock costs EUR 0.03 on October 16, 2026, down 14.56 percent on IDX.

Price pressure and valuation

Kalbe Farma stock fell 14.56 percent to IDR 675.00 on October 16, 2026.
Morgan Stanley retained an IDR 880.00 target dated September 16, 2026.
Kalbe Farma stock costs EUR 0.03 at Lang & Schwarz on October 16, 2026 at 4:01 p.m. CEST, down 14.56 percent on IDX.
Kalbe Farma traded at a P/E ratio of 8.48 with a market capitalization of IDR 30.5 trillion.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma stock fell 14.56 percent to IDR 675.00 on October 16, 2026, against a previous close of IDR 790.00 on the IDX. At Lang & Schwarz, the euro quotation stood at EUR 0.03 on October 16, 2026 at 4:01 p.m. CEST, while the Indonesian listing supplied the session move.

Analyst target remains above price

Morgan Stanley retained an IDR 880.00 target for Kalbe Farma on September 16, 2026, according to Investing.com. Against the IDR 675.00 session price, that target is 30.37 percent higher. The target gives the market a dated valuation marker even as the share price remains well below its yearly high.

Range and trading activity

Kalbe Farma traded between IDR 675.00 and IDR 720.00 during the October 16, 2026 session, with an opening price of IDR 700.00. Volume reached 144,024,400 shares, compared with an average volume of 72,996,752 shares. The session range of IDR 630.00 to IDR 1,345.00 places the latest price 49.81 percent below the 52-week high and 7.14 percent above the low.

A report dated October 8, 2026 said first-half net income was IDR 1.91 trillion, compared with IDR 1.97 trillion in the same period a year earlier, according to Dialektika Network. The result contrasts with the companys current market valuation and keeps profitability alongside sales growth as a key stock variable.

Valuation and peer comparison

Kalbe Farma has a market capitalization of IDR 30.5 trillion, a P/E ratio of 8.48 and a dividend yield of 0.03 percent. The 52-week range and volume figures are dated October 16, 2026.

Comparison with peers

Kalbe Farma (IDX, IDR): minus 14.56 percent, P/E 8.48, market capitalization IDR 30.5 trillion

Sido Muncul (IDX, IDR): minus 7.91 percent, P/E 9.96, market capitalization IDR 9.6 trillion

Kimia Farma (IDX, IDR): minus 13.86 percent, P/E minus 8.43, market capitalization IDR 1.9 trillion

Price position for investors

The Indonesian session placed Kalbe Farma below the IDR 790.00 prior close while the euro quotation remained at EUR 0.03 at Lang & Schwarz. The differing currencies describe separate listings and are not combined into one valuation measure.

Kalbe Farma was trading at EUR 0.03 at Lang & Schwarz on October 16, 2026 at 4:01 p.m. CEST, down 14.56 percent on the IDX versus the prior close of October 15, 2026. The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.